Embedded Files
In our laboratory, we have been conducting various projects of translational cancer research, particularly in advanced kidney cancer and prostate cancer. Currently, cancer genomics and precision oncology are the main research topic of our lab, particularly by using integrative cancer genomics data and patient-derived tumor organoids models. We are also performing several collaborating studies with interesting research topics, such as tumor-infiltrating T cells (TILs) as an immuno-oncology for understanding the mechanisms of treatment response and resistance of immune checkpoint inhibitors, as well as systems biology for discovering a novel biomarker to predict drug responsiveness in patients with metastatic kidney and prostate cancers.
In our laboratory, we have been conducting various projects of translational cancer research, particularly in advanced kidney cancer and prostate cancer. Currently, cancer genomics and precision oncology are the main research topic of our lab, particularly by using integrative cancer genomics data and patient-derived tumor organoids models. We are also performing several collaborating studies with interesting research topics, such as tumor-infiltrating T cells (TILs) as an immuno-oncology for understanding the mechanisms of treatment response and resistance of immune checkpoint inhibitors, as well as systems biology for discovering a novel biomarker to predict drug responsiveness in patients with metastatic kidney and prostate cancers.
Cancer genomics
Cancer genomics
In real-world practice, some patients repond well to immune-checkpoint blockade (ICB) (CR or PR), as shown in left panels, but, other patients do not respond after ICB treatment immediately (PD), which is the intrinsic resistance, as shown in right panels. Unfortunately, we do not fully understand this phenomenon, yet.
In real-world practice, some patients repond well to immune-checkpoint blockade (ICB) (CR or PR), as shown in left panels, but, other patients do not respond after ICB treatment immediately (PD), which is the intrinsic resistance, as shown in right panels. Unfortunately, we do not fully understand this phenomenon, yet.
In this regards, our research group has enormous efforts that emphasize the integration of various sequencing data, such as whole-transcriptomes and single-cell RNA sequencing data, for multiple purposes. This includes expanding our understanding of how functional genomic alterations mediate the response or resistance to novel cancer therapies, such as immune-checkpoint blockades and AR targeting agents. Our efforts can drive personalized medicine in patients with advanced kidney and prostate cancer.
In this regards, our research group has enormous efforts that emphasize the integration of various sequencing data, such as whole-transcriptomes and single-cell RNA sequencing data, for multiple purposes. This includes expanding our understanding of how functional genomic alterations mediate the response or resistance to novel cancer therapies, such as immune-checkpoint blockades and AR targeting agents. Our efforts can drive personalized medicine in patients with advanced kidney and prostate cancer.
Cell lineage heterogeneity related to ICB response in advanced ccRCC (Ahn et al., unpublished data)
Cell lineage heterogeneity related to ICB response in advanced ccRCC (Ahn et al., unpublished data)
Single cell transcriptomic profiling of prostate cancer accprding to the tumor location (Jee et al., unpublished data)
Single cell transcriptomic profiling of prostate cancer accprding to the tumor location (Jee et al., unpublished data)
Molecular subtypes correlate with the responsiveness to immune checkpoint inhibitors in metastatic ccRCC (Jee et al., Cancers 2022)
Molecular subtypes correlate with the responsiveness to immune checkpoint inhibitors in metastatic ccRCC (Jee et al., Cancers 2022)
Identification of key target gene of overcoming resistance of ART agents (Seo and Jee et al., FEBS Journal 2022)
Identification of key target gene of overcoming resistance of ART agents (Seo and Jee et al., FEBS Journal 2022)
Tumor organoids
Tumor organoids
A key research tool in our lab involves the tumor organoid from patients with advanced kidney and prostate cancer, particularly who are treated by existing and emerging cancer drugs. Our group is actively expanding these efforts across various clinical scenarios, including response/resistance to immune-check point inhibitors and novel AR targeting agents.
A key research tool in our lab involves the tumor organoid from patients with advanced kidney and prostate cancer, particularly who are treated by existing and emerging cancer drugs. Our group is actively expanding these efforts across various clinical scenarios, including response/resistance to immune-check point inhibitors and novel AR targeting agents.
Our pipeline of kidney cancer and prostate cancer organoid culture and analysis
Our pipeline of kidney cancer and prostate cancer organoid culture and analysis
Pt #6 (RCC), Normal organoid, P1
Pt #1 (RCC), Tumor organoid, P2
Pt #4 (Prostate cancer), Normal organoid, P1
Pt #3 (Prostate cancer), Tumor organoid, P2
Collaborators
Collaborators
Page updated
Google Sites
Report abuse